1. Home
  2. KYMR vs FUL Comparison

KYMR vs FUL Comparison

Compare KYMR & FUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KYMR
  • FUL
  • Stock Information
  • Founded
  • KYMR 2015
  • FUL 1887
  • Country
  • KYMR United States
  • FUL United States
  • Employees
  • KYMR N/A
  • FUL N/A
  • Industry
  • KYMR Medicinal Chemicals and Botanical Products
  • FUL Home Furnishings
  • Sector
  • KYMR Health Care
  • FUL Industrials
  • Exchange
  • KYMR Nasdaq
  • FUL Nasdaq
  • Market Cap
  • KYMR 3.1B
  • FUL 3.3B
  • IPO Year
  • KYMR 2020
  • FUL N/A
  • Fundamental
  • Price
  • KYMR $44.64
  • FUL $62.95
  • Analyst Decision
  • KYMR Strong Buy
  • FUL Hold
  • Analyst Count
  • KYMR 16
  • FUL 5
  • Target Price
  • KYMR $58.94
  • FUL $67.25
  • AVG Volume (30 Days)
  • KYMR 865.2K
  • FUL 604.1K
  • Earning Date
  • KYMR 08-06-2025
  • FUL 06-25-2025
  • Dividend Yield
  • KYMR N/A
  • FUL 1.47%
  • EPS Growth
  • KYMR N/A
  • FUL N/A
  • EPS
  • KYMR N/A
  • FUL 1.84
  • Revenue
  • KYMR $58,885,000.00
  • FUL $3,527,969,000.00
  • Revenue This Year
  • KYMR $58.26
  • FUL N/A
  • Revenue Next Year
  • KYMR N/A
  • FUL $3.24
  • P/E Ratio
  • KYMR N/A
  • FUL $34.39
  • Revenue Growth
  • KYMR N/A
  • FUL N/A
  • 52 Week Low
  • KYMR $19.45
  • FUL $47.56
  • 52 Week High
  • KYMR $53.27
  • FUL $87.67
  • Technical
  • Relative Strength Index (RSI)
  • KYMR 55.84
  • FUL 61.73
  • Support Level
  • KYMR $43.56
  • FUL $60.62
  • Resistance Level
  • KYMR $46.34
  • FUL $64.90
  • Average True Range (ATR)
  • KYMR 1.81
  • FUL 1.83
  • MACD
  • KYMR -0.60
  • FUL 0.39
  • Stochastic Oscillator
  • KYMR 36.21
  • FUL 81.71

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

About FUL H. B. Fuller Company

H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.

Share on Social Networks: